BeyondSpring to present Phase 2 plinabulin combo study in resistant NSCLC at ASCO 2026

BeyondSpring Inc.

BeyondSpring Inc.

BYSI

0.00
  • BeyondSpring flagged new Phase 2 data from Study 303 in metastatic non-small cell lung cancer patients whose disease progressed on PD-1/PD-L1 inhibitors, with results scheduled for future presentation at the 2026 ASCO Annual Meeting.
  • The poster will cover efficacy and immune profiling for a regimen combining plinabulin, docetaxel, and pembrolizumab in second- or third-line treatment.
  • Disclosure at ASCO is set for May 31, 2026, in a lung cancer session in Chicago.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180700PRIMZONEFULLFEED9721914) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.